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Edited by Vladimir SkulachevAbstract Cepharanthine (CEP), a biscoclaurine alkaloid, has
been reported to induce cell death, however, the molecular mech-
anism of this phenomenon remains unclear. We herein report
that CEP induced apoptosis in HuH-7 cells through nuclear
fragmentation, DNA ladder formation, cytochrome c release,
caspase-3 activation and poly-(ADP-ribose)-polymerase cleav-
age. CEP triggered the generation of reactive oxygen intermedi-
ates, the activation of mitogen activated protein kinase (MAPK)
p38, JNK1/2 and p44/42, and the downregulation of protein ki-
nase B/Akt. Antioxidants and SP600125, an inhibitor of JNK1/
2, but not inhibitors of p38 MAPK and MEK1/2, signiﬁcantly
prevented cell death, thus implying that reactive oxygen species
and JNK1/2 play crucial roles in the CEP-induced apoptosis of
HuH-7 cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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SP6001251. Introduction
Cepharanthine (CEP) is a natural alkaloid extracted from
Stephania cepharantha Hayata [1], which has been widely used
in Japan for the treatment of snake venom-induced hemolysis
bronchial asthma and other types of allergic inﬂammation,
alopecia areata, and leukopenia during radiation therapy or
anti-cancer treatment without any serious side eﬀects [2,3].
Okamoto et al. reported that CEP inhibits HIV-1 replication,
suppresses PMA-induced production of inﬂammatory cyto-
kine and a chemokine in monocyte/macrophage cultures, and
also protects diﬀerentiated human neuroblastoma cells death
induced by TNF-a and gp120 [3]. CEP has also been shown
to prevent vascular injury induced by LPS [4]. Goto et al. dem-Abbreviations: CEP, cepharanthine; JNK, c-Jun N-terminal kinase;
MAPK, mitogen activated protein kinase; ROS, reactive oxygen spe-
cies; NAC, N-acetyl cysteine; PARP, poly-(ADP-ribose)-polymerase
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doi:10.1016/j.febslet.2005.12.048onstrated that CEP is beneﬁcial for the treatment of newborn
endotoxic shock [5]. Evidence is accumulating supporting the
hypothesis that CEP potentiates the activity of some anti-can-
cer agents and restores the eﬀect of anti-cancer drugs in multi-
drug-resistance cancer cells possibly through perturbing the
plasma membrane function in order to increase the intracellu-
lar accumulation of anti-cancer drugs [2,6]. Some recent re-
ports have provided evidence that CEP itself displays both a
direct anti-tumor eﬀect, thereby inhibiting the growth of Ehr-
lich ascites tumors [7] and inducing apoptosis in human leuke-
mia cell lines [8] as well as an indirect anti-tumor eﬀect by
interacting positively with human interferon [9]. Nakajima
et al. recently reported that CEP co-treatment enhances the
cytotoxicity of doxorubicine resistant hepatocellular carci-
noma cell lines [10]. Nishikawa et al. have shown that CEP en-
hances adriamycin accumulation in cancer cells but lowers its
accumulation in normal liver cells in both, in vitro and
in vivo [11], thus suggesting that CEP plays a beneﬁcial role
in potentiating the eﬀect of chemotherapy on the drug resis-
tance of hepatocellular carcinoma.
The family of serine–threonine protein kinases plays an
important role in apoptosis and survival signaling pathways.
The major components belonging to this family are p38 mito-
gen activated protein kinase (MAPK), c-Jun N-terminal ki-
nase (JNK), extracellular-signal regulating kinase1/2 (ERK1/
2 or p44/p42), and protein kinase B (PKB or Akt), which
are activated in response to a variety of stimuli. JNK and
p38 MAPK signaling molecules are predominantly activated
by the inﬂammatory cytokines, environmental stress, and oxi-
dative stress, thus leading to cell diﬀerentiation and apoptosis
[12–14]. p44/42 MAPK and Akt, on the other hand, are pref-
erentially activated by mitogen through the Ras/Raf/MEK
(MAP kinase kinase) and Ras/PI3-K signaling pathways,
respectively; thus leading to cell growth and survival [15].
Although it has been reported that CEP causes death in hepa-
tocellular carcinoma cell lines [10], to the best of our knowl-
edge there have so far been no reports available on the
mechanism of hepatocellular carcinoma cell death induced
by CEP. The present study was undertaken to investigate
the eﬀect of CEP on human hepatocellular carcinoma using
a human hepatocellular carcinoma cell line, HuH-7, and the
underlying intracellular signal transduction pathways in-
volved. We herein show evidence that CEP induced apoptosisblished by Elsevier B.V. All rights reserved.
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cies (ROS), the activation of stress activated kinase JNK1/2,
MAPK p38, and ERK p44/42, and the downregulation of
the protein kinase B (Akt).2. Materials and methods
2.1. Reagent
CEP was purchased from Kaken Shoyaku Co. Ltd. (Tokyo, Japan).
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) was purchased from Dojindo (Kumamoto, Japan). Hoechst
33258 (Bisbenzimide H33258) ﬂuorochrome and phenylmethylsulfonyl
ﬂuoride were purchased from Wako Pure Chem. Inc. Ltd. (Osaka, Ja-
pan). Protease inhibitor (complete cocktail) was purchased from Boeh-
ringer–Mannheim (Germany). Hundred base pairs DNA ladder size
marker was bought from Invitrogen (California, USA). N-Acetyl cys-
teine (NAC) and 5,6-carboxy-2,7-dichloroﬂuorescein-diacetate
(DCFH-DA) were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). N-t-Butyl-a-phenylnitrone (PBN) was purchased from
ICN Biomedicals, Inc. (Ohio, USA). SB203580, SP600125 and Cas-
pase-3 inhibitor 1 were obtained from Calbiochem (San Diego, CA,
USA). U0126 was obtained from Promega (Madison, WI, USA).
CPP32-like protease activity assay kit was purchased from MBL (Na-
goya, Japan). Any other chemicals not speciﬁcally cited here were pur-
chased from the Sigma Chemicals (St. Louis, MO, USA).2.2. Antibodies
The polyclonal antibodies to p38, JNK/SAPK, and phospho-p38,
phospho-JNK/SAPK, phospho-Akt (serine-473), ATF-2, phospho-
ATF-2, and themonoclonal antibodies toAkt were purchased fromCell
Signaling Technology (MA, USA). b-Actin and poly-(ADP-ribose)-
polymerase (PARP) were purchased from Sigma (St. Louis, MO,
USA) andOncogene (Cambridge,MA,USA), respectively. Cytochrome
c antibody was obtained from PharMingen (San Diego, CA, USA).2.3. Cells and cell culture
Human hepatocellular carcinoma cell line, HuH-7, was obtained
from the RIKEN Cell Bank (Tsukuba, Japan) and cultured in 10%
FBS-containing DMEM media (Gibco-BRL, USA) with the appropri-
ate antibiotics at 37 C in the presence of a humidiﬁed atmosphere of
air (95%) and CO2 (5%). All experiments were performed in the pres-
ence of a low serum (0.1% serum).2.4. Cell viability test
MTT assays were applied to test cell viability, as described by Biswas
et al. [16]. In brief, the cells were seeded at a density of 2–3 · 104 cells
per well in 96-well dishes. The cells were then incubated under various
conditions as indicated. Subsequently, MTT (0.5 mg/ml ﬁnal conc.)
was added to each well. After 3 h of additional incubation, 100 ll of
a solution containing 10% SDS (pH 4.8) plus 0.01 N HCl was added
to dissolve the crystals. The absorption values at 570 nm were deter-
mined with an automatic ELISA plate reader (Immuno Mini
NJ-2300, Japan).2.5. Nuclear staining with Hoechst 33258
Morphological changes in the nuclear chromatin of cells undergoing
apoptosis were detected by staining with Hoechst 33258 ﬂuorochrome
as described by Biswas et al. [16].2.6. DNA fragmentation assay
To characterize the cell death pattern, DNA ladder assays were per-
formed as previously described [16]. Brieﬂy, 106 cells were lysed in
100 ll of 10 mM Tris–HCl buﬀer (pH 7.4) containing 10 mM EDTA
and 0.5% Triton X-100. After centrifugation for 5 min at
15,000 rpm, supernatant samples were treated with RNase A and pro-
tenase K. Subsequently, 20 ll of 5 M NaCl and 120 ll isopropanol
were added to the samples and kept at 20 C for 6 h. Following cen-
trifugation for 15 min at 15,000 rpm, the pellets were dissolved in 20 llof TE buﬀer (10 mM Tris–HCl and 1 mM EDTA) as loading samples.
To assay the DNA fragmentation pattern, samples were loaded onto
1.5% agarose gel and electrophoresis was carried out.
2.7. ROS assay
The formation of intracellular H2O2 as production was determined
using dichloroﬂuorescein diacetate (DCFH-DA) as previously de-
scribed [16].
2.8. Preparation of the cytosolic fractions, cell lysates, and Western
blotting
Cellular fractions and Western blotting were carried out as described
by Sarker et al. [14].
2.9. Assay of caspase-3/CPP32 enzyme activity
Caspase-3 enzyme activity was analyzed according to the manufac-
ture’s instructions as described by Sarker et al. [17].
2.10. Statistical analysis
All experiments were performed in triplicate. The results of multiple
observations were presented as the means ± S.D. of at least three sep-
arate experiments. Statistical signiﬁcance was determined by Student’s
t-test. A value of p < 0.05 was considered to be signiﬁcant.3. Results
3.1. CEP induces apoptosis in hepatocellular carcinoma cells
We evaluated for the ﬁrst time the eﬀect of CEP on the via-
bility of hepatoma cells by stimulating HuH-7 cells with vari-
ous concentrations of CEP in the presence of a low serum
(0.1%) for 24 h. As shown in Fig. 1A, CEP dose dependently
triggered cell death. Cell death was not signiﬁcantly observed
up to 10 lM CEP exposure but a marked decrease in cell via-
bility (74 ± 8%) was observed at 15 lM CEP, which in turn
sharply decreased to (60 ± 7%) when cells were exposed to
20 lM CEP. Fig. 1B shows that the cells shrank, became
rounded, and the phase became bright in response to CEP
treatment which was consistent with the results presented
above. We then investigated the eﬀects of CEP on the cell via-
bility over time. A loss of cell viability was evident at 6 h
(89 ± 5%), which in turn, noticeably increased to (77 ± 8%)
at 12 h and a sharp increase (60 ± 7%), 24 h after 20 lM of
CEP exposure (data not shown). Because chromatin condensa-
tion, nuclear fragmentation and DNA ladder formation are
notable features of programmed cell death [18,19], we next
sought, to examine whether CEP-induced cell death was fol-
lowed by these features. In response to CEP (20 lM), both
chromatin condensation and nuclear fragmentation were ob-
served by ﬂuorescence microscopy (Fig. 1C) and DNA ladder
formation was detected by agarose gel electrophoresis
(Fig. 1D), thus suggesting that CEP-induced HuH-7 cell death
was due to apoptosis.
3.2. CEP induces the production of ROS
We then examined whether or not CEP-induced cell death
was followed by oxidative stress. As shown in Fig. 2, CEP at
a dose of 20 lM, which caused a signiﬁcant degree of apopto-
sis, also caused a marked induction of ROS. Consistent with
this result, NAC and PBN, speciﬁc scavengers of ROS, signif-
icantly attenuated CEP-induced apoptosis (cells viability in-
creased to 85 ± 8% and 88.86 ± 7% by the pretreatment of
cells with 500 lM of either NAC and PBN, respectively (data
not shown), thus suggesting that CEP induced HuH-7 cell
death followed by oxidative stress.
Fig. 1. CEP induces apoptosis in HuH-7 cells. The cells were subjected to various concentrations of CEP for 24 h (A). Cell viability was determined
by an MTT assay. The data shown are the percentages of the control values ± S.D. (*p < 0.05 vs. control). Microscopic observations of cell
morphology (B,C) in the absence (left panels) or in the presence (right panels) of 2 lMCEP. (B) The phase contrast (original magniﬁcation 200·). (C)
Hoechst staining (original magniﬁcation 400·). Note that the cells which stimulated with CEP exhibited apoptotic features characterized by
condensed/fragmented nuclei. (D) DNA ladder formation. The cells were treated with the indicated concentrations of CEP for 24 h and an
internucleosomal DNA fragmentation was analyzed on 1.5% agarose gel electrophoresis. M, indicates the 100-bp DNA ladder size marker. The data
shown are the representatives of three independent experiments.
Fig. 2. CEP causes the generation of ROS. The cells were treated with
20 lM CEP for 1 h in the presence of DCFH-DA and then harvested,
and the ﬂuorescence of ROS was evaluated by FACS analyzer. Note
that CEP caused a marked induction of ROS. The data shown are the
representatives of three independent experiments.
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ERK1/2
Based on these ﬁndings, we sought to examine whether CEP-
induced hepatoma cell death was accompanied by the activa-
tion of common pro-apoptotic signaling pathways. CEP was
found to activate JNK and p38MAPK, which mediate apopto-
sis in diﬀerent experimental models [12–14]. The phosphoryla-
tion of both JNK and p38 MAPK was time-dependently
induced by CEP (Fig. 3A). p38 MAPK and JNK activation
could be detected within 7.5 min, and dramatically increased
for 1 h, and thereafter was sustained for 4 h. Consistent with
such JNK and p38 MAPK activation, CEP induced the activa-
tion of c-Jun (Ser 73) and ATF-2, the down-stream targets of
JNK and p38. We also observed that ERK1/2 and Akt, which
are generally known to promote cell survival [15] were reversely
regulated in response to CEP. A marked activation of ERK1/2
was detectable at 7.5 min which thereafter maintained constant
levels for 4 h, whereas protein kinase B (Akt) was downregu-
lated in response to CEP. We next evaluated the possible roles
of these activated kinases in CEP-induced cell death. As shown
in Fig. 3B, a potent and a speciﬁc inhibitor of JNK, SP600125,
noticeably blocked CEP-induced cell death (the cell viability in-
creased from 60 ± 7% to 87 ± 7%), while SB203580, a speciﬁc
Fig. 3. CEP triggers the activation of p38, ATF-2, JNK, c-Jun, and p44/42 and downregulation of Akt. (A) The cells were stimulated with 20 lM of
CEP for the indicated time periods and the activation and expression levels of diﬀerent kinases and the indicated transcription factors were
determined by immunoblotting as described in Section 2. (B,C) The eﬀects of SB203580 and SP600125, and U0126 and LY290042 on CEP-induced
apoptosis. The cells were pretreated with various concentrations of SB (SB203580: 1, 2.5, 5, and 10 lM) and SP 1 (SP600125: 1 lM), and U0 (U0126:
0.5, 1, 2.5, and 10 lM) and LY (LY290042: 0.5, 1, 5, and 10 lM), which are all speciﬁc and potent inhibitors of p38 and JNK &MEK1/2 and PI3-K,
respectively, for 1 h. Cell viability was determined after a 24-h exposure of 20 lM CEP. The data shown are the percentages of the control
values ± S.D. (*p < 0.05 vs. CEP).
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enhanced CEP-induced cell death (the cell viability signiﬁcantly
decreased from 60 ± 7% to 44 ± 8% in the presence of 10 lM
SB203580). Like SB203580, pretreatment of cells with U0126,
a potent and speciﬁc inhibitor of MEK1/2, the up-stream of
p44/42 signaling molecule, as well as LY29004, a speciﬁc inhib-
itor of PI3-K, the up-stream of Akt, could not prevent CEP-in-
duced cell death (Fig. 3C). We also found that U0126, and
SB203580, blocked activation of ERK1/2, and p38, respectively
(data not shown). Data presented above indicates that ROS
generation and JNK activation are positively correlated with
CEP-induced apoptosis of HuH-7 cells. It is of interest to exam-
ine whether ROS act up- or down-stream of JNKs. We found
that pretreatment of cells with either NAC or PBN completely
blocked CEP-induced ROS accumulation, whereas failed to in-
hibit JNK activation (data not shown). Alternatively,
SP600125 did not aﬀect CEP-induced ROS production (data
not shown), indicating that ROS production and JNKs activa-
tion represent two independent pathways.
3.4. CEP triggers cytochrome c release and PARP cleavage
Biochemical events such as the release of cytochrome c from
mitochondria into cytosol, caspases activation, and PARP
cleavage occur during mitochondrial-mediated apoptotic celldeath. We therefore investigated whether CEP-induced cell
death was also followed by these biochemical events. We no-
ticed that after a 2-h exposure of CEP, cytochrome c was
detectable and it signiﬁcantly increased at 4 h in the cytoplas-
mic protein fraction (Fig. 4A). CEP has been shown to activate
caspase-3 in jurkat cell apoptosis [8]. In addition, the release of
cytochrome c into cytosol has been well documented to trigger
caspase activation, thus resulting in cell death. As shown in
Fig. 4B, CEP stimulated a 4.2 ± 0.3-fold increase in caspase-
3-like activities at 12 h and the treatment of HuH-7 cells with
a speciﬁc and potent inhibitor of caspase-3 signiﬁcantly
blocked CEP-induced apoptotic cell death (cells viability in-
creased to 82 ± 8% in the presence of 10 lM caspase-3 inhibi-
tor, data not shown), thus indicating the CEP-induced cell
death followed by caspase-3 activation. Once caspase-3 is acti-
vated, a number of cellular proteins are cleaved, including
PARP. To further conﬁrm the activation of caspase-3 in
CEP-induced cell death, we determined the PARP cleavage
by Western blotting. As shown in Fig. 4C, CEP treatment
markedly induced PARP cleavage, thus suggesting that mito-
chondrial events were also associated with the CEP-induced
hepatoma cell death process. We further investigated whether
or not ROS production and JNK activation occur up-stream
of mitochondria. For this purpose, cells were pretreated with
Fig. 4. CEP induces the cytochrome c release from the mitochondria and PARP cleavage via caspase-3 activation. (A) The cells were treated with
CEP for the indicated periods of time and the cytosolic fractions were analyzed for the levels of cytochrome c (Cyt c, upper panel) by
immunoblotting. b-Actin was used for the loading control (lower panel). Blots represent three experiments. (B) The cells were treated with 20 lM of
CEP for 12 h. At the end of the treatment, caspase-3 like protease activity was assayed. The data are the means of ±S.D. (*p < 0.05 vs. CEP) of three
individual experiments. (C) PARP cleavage in CEP-treated cells was determined by immunoblotting. Blot represents four experiments. (D) The cells
were pretreated with NAC (500 lM) or SP600125 (1 lM) and then exposed to 20 lM of CEP for 4 h and the cytosolic fractions were analyzed for the
levels of cytochrome c by immunoblotting. Blot represents three experiments.
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CEP, and cytochrome c release was evaluated. As shown in
Fig. 4D, both of NAC and SP600125 partially blocked CEP-
induced cytochrome c release. On the other hand, caspase-3
inhibitor did not aﬀect either ROS generation or JNKs activa-
tion induced by CEP (data not shown), suggesting that ROS
and JNK are up-stream players in the CEP-induced HuH-7
cells death (Fig. 5).4. Discussion
In the present study, we demonstrated that CEP induces
apoptosis in human hepatocellular carcinoma, HuH-7 cells,Fig. 5. A putative model for the CEP-iin a dose- and time-dependent fashion. CEP induced cell death
followed by chromatin condensation, nuclear fragmentation,
and DNA ladder formation, which are the hallmark features
of apoptosis [18,19] in HuH-7 cells. Our ﬁndings are consistent
with the ﬁndings of previous reports which demonstrated that
CEP induces apoptosis in human leukemia cell lines, Jurkat
and K562, murine P388 doxorubicin-sensitive (P388), and
resistant (P388/Dox) cells [8,20]. We also investigated the link-
age between oxidative stress and cell death. Our results showed
that CEP treatment conferred oxidative stress to the cells
(Fig. 3A) and these results are in line with recent reports that
CEP (1–10 lg/ml) induced ROS in murine p388 doxorubicin-
resistance (p388/Dox) cells even though CEP did not induce
ROS in murine doxorubicin-sensitive (p388/S) cells [20].nduced apoptosis of HuH-7 cells.
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ROS have also been published. For example, Aakamatsu
et al. reported that CEP is an eﬀective ROS scavenger as it sig-
niﬁcantly reduces the levels of ROS generated by neutrophils
[21]. These diﬀerences in their ﬁndings may be due to diﬀer-
ences in the cell types.
The family of MAPKs play a key role in cell survival/death
in many physiological and pathological settings. It is well doc-
umented that JNK or p38 MAPK activation leads to apoptosis
in various experimental model systems [13,14]. A study by
Ghatan et al. has shown that p38 MAPK can induce mito-
chondrial translocation of Bax in neurons undergoing oxida-
tive stress-induced apoptosis [22]. Recently, we have reported
that JNK and p38 MAPK are activated and positively corre-
lated in oxidative stress-induced cell death [14,23]. However,
contradictory ﬁndings have also been reported. For example,
p38 MAPK was not implicated in the death of WEHI-231
and NIH3T3 cells [24]. On the other hand, the p38 MAPK is
required for proliferation of leukemia, lymphoma cell lines
[25]. JNK activation has been found to have no role in
TNF-a-mediated apoptosis in MCF-7 cells [26]. Moreover,
JNK activity has been shown to be required for growth of
T98G glioblastoma [27]. A growing body of evidence shows
that JNK activation plays pro-apoptotic role only if its activa-
tion is prolonged [13,28,29]. The process of cell survival occurs
in conjunction with apoptosis, resulting in the inhibition or de-
lay of apoptotic cell death. Activation of p44/42 MAPK and
protein kinase B (Akt) are generally associated with cell prolif-
eration and survival [15]. In contrast, p44/42 has been found to
be activated in various apoptotic models. Recently, p44/42
MAPK activation has been demonstrated to be essential in cis-
platin-induced apoptosis [30].
In the present study, we found that CEP triggered the acti-
vation of JNK, p38 MAPK, and p44/42 and the downregula-
tion of Akt. We examined the functional relationship between
the MAPK activity and the cell death process and thus ob-
served that the JNK activity, but not the p38 or p44/42 MAPK
activity, played an essential role in CEP-induced apoptosis
(Fig. 3B and C) as SP600125, the pharmacological inhibitor
of JNK but not U0126 or SB203580 signiﬁcantly abrogated
CEP-induced apoptosis, thus suggesting that p38 MAPK and
p44/42 may not be involved in CEP-induced cell death. It
has been reported that SB203580 can activate the Raf-1 activ-
ity in quiescent smooth-muscle cells [31]. JNK activation has
also been reported to be inhibited by a p38 MAPK inhibitor
[32]. To rule out any non-speciﬁc function of SB203580 and
U0126 that might occur, specially, at a higher concentration,
we incubated the cell with a wide range of concentrations
(nanomolar to micromolar) of these inhibitors. However, we
did not notice any change of JNK, p44/42 activation, or cell
death by SB203580 (data not shown). Actually, the p38
MAPK subfamily which consists of p38a, p38b, p38c, and
p38d isoforms has been shown to play diﬀerent roles. Nemoto
et al. reported that p38a induces apoptosis, whereas p38b
inhibits apoptosis, indicating that each member of the p38
MAPK subfamily has unique role in apoptosis [33].
SB203580, the pyridinyl imidazole compound that was used
in the present study for blocking the p38 MAPK, has been re-
ported to inhibit a and b isoforms, while the c and d isoforms
are insensitive to this compound [33]. Hence, we cannot rule
out the possibility of opposite roles that may be played by
other isoforms of p38 MAPK in CEP-induced HuH-7 cellapoptosis. However, our results are partly in agreement with
the ﬁndings of Wu et al. who reported that p38 plays an
anti-apoptotic role, while p44/42 appeared to be a pro-apopto-
tic player in CEP-induced Jurkat and K562 cells [8]. Wu et al.
also demonstrated that CEP did not cause the activation of
JNK in either Jurkat and K562 cells [8]. Interestingly, we ob-
served a marked activation of JNK as well as its down-stream
target, c-Jun (serine 73) in HuH-7 cells in a time dependent
fashion and the JNK activity was found to be required for
the induction of cell death. Wu et al. reported that CEP in-
duces a marked activation of p44/42 in K562 cells but not in
Jurkat cells [8]. Therefore, it appears that ROS, JNK, and
p44/42 mediate CEP-induced cell death in a cell type speciﬁc
manner. The generation of ROS and the activation of p38
MAPK and JNK are correlated with apoptosis in many cell
types. It has been reported that stress-activated MAPKs (p38
and JNK) can be activated in a ROS-dependent as well as
independent manner [29,34,35]. JNK dependent mitochondrial
damage has also been shown in oxidative stress-induced cell
death [36]. We observed that ROS and JNK are positively cor-
related with CEP-induced HuH-7 cells death. We are therefore
interested in investigating the link between JNK activation and
ROS production. We found that inhibition of ROS production
did not prevent activation of JNK, whereas inhibition of JNK
did not suppress ROS accumulation (data not shown). These
observations suggest that JNK activation and ROS production
represent two independent pathways in the CEP-induced cell
death. The important issue that arises in this study is how
JNK is activated in CEP-induced cell death. There are several
lines of evidence that vanadate can trigger phosphorylation of
JNK independently of ROS [35]. Clerk et al. reported that fac-
tors other than ROS are involved in the activation of SAPKs/
JNKs during ischemia/reperfusion [37]. Although the exact
signaling pathway for ROS-independent JNK activation in
CEP-induced cell death remains to be elucidated, one possible
mechanism could be that CEP treatment somehow causes tyro-
sine phosphorylation in JNK or inhibits phosphatases in HuH-7
cells, resulting in activation of JNK and cell death.
In addition, we found that CEP treatment caused a down-
regulation of PKB/Akt and pretreatment of cells with
LY29004 instead of prevention, signiﬁcantly enhanced CEP-
induced cell death indicating that Akt might have a survival
role in CEP-induced HuH-7 cell death. Our results are sup-
ported by the recent ﬁndings that FTY720, a novel anti-cancer
agent, induces apoptosis in hepatoma cell lines both in vitro
and in vivo by downregulating Akt [38]. As a result, our ﬁnd-
ings suggest that CEP-induced HuH-7 cell apoptosis is accom-
panied by the activation of JNK and the downregulation of
Akt. The release of cytochrome c and other apoptogenic fac-
tors from the injured mitochondria has been shown to activate
caspases [39]. Caspases can modulate p38 MAPK/JNK activa-
tion in TNF-a or Fas-induced apoptosis [40] and caspase
inhibitor can attenuate p38/JNK activation [41], thus suggest-
ing that these stress-activated kinases may be dependent upon
caspase activation. However, JNK-mediated caspase activa-
tion has also been reported [42]. We observed that CEP-in-
duced apoptosis was accompanied by the mitochondrial
release of cytochrome c followed by the activation of cas-
pase-3 and cleavage of PARP (Fig. 4A–C). Our results also
show that a potent inhibitor of caspase-3 signiﬁcantly abro-
gated cell death (data not shown), thus implying that cas-
pase-3 protease is involved in the CEP-induced apoptosis of
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ing that CEP induces apoptosis in human leukemia and adeno-
squamous cell carcinoma cell lines through the activation of
caspase-3 and the induction of PARP cleavage [8,43]. Further-
more, NAC and SP600125 partially inhibited CEP-induced
cytochrome c release (Fig. 4D). We also observed that cas-
pase-3 inhibitor failed to inhibit ROS generation and JNK
activation (data not shown), thus implying that ROS genera-
tion and JNK activation may be up-stream of mitochon-
drial-associated events in CEP-induced HuH-7 cells death.
Although the exact mechanism through which /JNK activation
leads to cytochrome c release is not clear in the present study
and warrants further investigation, however, it seems that,
activated JNK and down-stream c-Jun play some roles in reg-
ulating expression levels of Bcl-2 and Bax which may in turn
cause mitochondrial injury and release of cytochrome c. Lee
et al. recently reported that luteolin-induced activation of
JNK causes the mitochondrial translocation of Bax, cyto-
chrome c release, and caspase-3 activation in human hepa-
toma, HepG2 cells [44]. Taken together, our results suggest
that the production of ROS, the activation of JNK, and down-
regulation of Akt play crucial roles in CEP-induced apoptosis
of hepatocellular carcinoma, HuH 7 cells.
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